Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL

Enrollment

181

Participants

Timeline

Start Date

November 29, 2016

Primary Completion Date

November 29, 2023

Study Completion Date

November 14, 2024

Conditions

Graft vs. Host Disease

Interventions

DRUG

Obinutuzumab

B cell depletion

DRUG

Placebo

Trial Locations (5)

Masonic Cancer Center, Minneapolis

Huntsman Cancer Institute, Salt Lake City

Stanford University, Palo Alto

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Roche-Genentech

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02867384 - Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation | Biotech Hunter | Biotech Hunter